Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Mulls European Stock Listing to Increase Funding

NEW YORK, March 9 (GenomeWeb News) - Galapagos Genomics, a privately held Belgian genomics-tool and drug-discovery firm, said today that it is considering listing its stock on the Euronext stock exchange this year.

The firm, one-fifth of which is owned by Crucell, a Dutch biotech company, said it is mulling the listing to drum up additional funding for its drug-discovery operations, which primarily target bone and joint diseases, such as osteoporosis and rheumatoid arthritis.

According to Galapagos' website, revenues and private financing have increased significantly in the past few years. It received a 23 million ($30.7 million) private placement in 2002 that brought the total amount of financing raised since inception to 32 million. Galapagos also reported a 20-percent increase in revenues in 2004, compared to fiscal year 2003.

The company this year also announced that it had licensed drug targets to Boehringer Ingelheim and GlaxoSmithKline.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.